基于16S rDNA测序探讨益气活血解毒方对老年肺源性脓毒症患者肠道菌群的影响:多中心前瞻性随机双盲对照试验
该多中心前瞻性随机双盲对照试验纳入55例老年肺源性脓毒症患者,观察组在常规西药治疗基础上加用益气活血解毒方(人参15 g、三七9 g、大黄3 g,温水50 mL溶解)口服或鼻饲,每日2次,疗程7天,对照组给予安慰剂。第7天观察组血清降钙素原、APACHE II评分及胃肠功能衰竭评分下降幅度均显著优于对照组。16S rDNA测序显示两组肠道菌群α多样性(Simpson指数)均较基线显著降低,但组间无显著差异;β多样性提示三组菌群结构存在差异。属种水平上,观察组Erysipelatoclostridium和Faecalibacterium增加,Bacteroides、Bilophila、Eggerthella和Collinsella减少。作者认为Bacteroides、Erysipelatoclostridium和Collinsella可能是潜在微生物靶点。
要点
- 老年肺源性脓毒症患者在常规西药基础上加用益气活血解毒方(人参15 g、三七9 g、大黄3 g,温水50 mL溶解,口服或鼻饲,每日2次,疗程7天)后,第7天降钙素原、APACHE II评分及胃肠功能衰竭评分下降幅度均显著优于安慰剂对照组。
- 55例患者中对照组29例、观察组26例,两组性别、年龄、合并症及基线SOFA、APACHE II、AGI分级评分、GIF评分均无显著差异。
- 肠道菌群α多样性:观察组与对照组Simpson指数均较基线组显著降低[观察组0.75(0.53, 0.91)、对照组0.81(0.32, 0.91)vs 基线组0.88(0.87, 0.89),均P<0.05],但观察组与对照组之间无显著差异。
- β多样性分析提示三组菌群结构存在差异(R2=0.096,P=0.026);属水平38个菌属有显著差异,观察组较对照组Erysipelatoclostridium(P=0.014)和Faecalibacterium(P=0.013)增加,Bacteroides(P=0.009)、Bilophila(P=0.005)、Eggerthella(P=0.002)和Collinsella(P=0.043)减
- LEfSe分析提示Lactobacillus salivarius、Erysipelatoclostridium、Collinsella、Cloacibacillus和Bacteroides为关键判别菌群。
适用人群与场景
- 2020年11月至2021年10月入住广东省中医院急诊科、芳村医院ICU及大学城医院ICU的老年肺感染所致脓毒症患者。
- 纳入标准为老年肺源性脓毒症患者;排除标准原文未报告。
处置流程与药物剂量
- 两组均接受常规西药治疗。
- 观察组在常规西药治疗基础上加用益气活血解毒方(人参15 g、三七9 g、大黄3 g,温水50 mL溶解),口服或鼻饲,每日2次,疗程7天。
- 对照组给予安慰剂。
- 治疗前及治疗第5–7天采集临床资料及新鲜粪便样本,行16S rDNA测序及生物信息学分析(α多样性、β多样性、LEfSe分析)。
研究设计与关键结果
- 研究类型为多中心前瞻性随机双盲对照试验,共纳入55例老年肺源性脓毒症患者,对照组29例、观察组26例。
- 两组性别、年龄、合并症及基线SOFA评分、APACHE II评分、AGI分级评分、GIF评分均无显著差异。
- 与对照组相比,观察组第7天血清降钙素原、APACHE II评分显著降低,GIF评分下降幅度更大。
- 共采集粪便样本:治疗前基线组30份、对照组治疗后29份、观察组治疗后26份。
- α多样性:观察组与对照组Simpson指数均较基线组显著降低[观察组0.75(0.53, 0.91)、对照组0.81(0.32, 0.91)vs 基线组0.88(0.87, 0.89),均P<0.05],观察组与对照组之间无显著差异;Chao1、Ace、Shannon指数三组间无显著差异。
- β多样性分析提示三组菌群结构存在差异(R2=0.096,P=0.026)。
- 门水平以Firmicutes(53.69%)、Actinobacteria(16.23%)、Proteobacteria(15.39%)和Bacteroidetes(9.57%)为主,组间无显著差异。
- 属水平38个菌属有显著差异:观察组较对照组Erysipelatoclostridium(P=0.014)和Faecalibacterium(P=0.013)增加,Bacteroides(P=0.009)、Bilophila(P=0.005)、Eggerthella(P=0.002)和Collinsella(P=0.043)减少。
证据类型、等级与局限
- 证据类型:多中心前瞻性随机双盲对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,益气活血解毒方联合常规治疗可改变老年肺源性脓毒症患者的肠道菌群结构,Bacteroides、Erysipelatoclostridium和Collinsella为潜在微生物靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effects of the combined Yiqi Huoxue Jiedu formula (YHJF) on intestinal microbiota in elderly patients with pulmonary-derived sepsis and identify potential microbial targets.
METHODS: A prospective randomized double-blind controlled trial was conducted. Elderly patients with pulmonary infection-induced sepsis admitted to the emergency department of Guangdong Provincial Hospital of Traditional Chinese Medicine (TCM), intensive care unit (ICU) of Fangcun Hospital, and ICU of Daxuecheng Hospital, from November 2020 to October 2021 were enrolled and randomized into two groups. Both groups received conventional Western medicine treatment. The observation group additionally received YHJF (composed of 15 g of Panax ginseng, 9 g of Panax notoginseng, and 3 g of Rheum palmatum, dissolved in 50 mL warm water) orally or via nasogastric tube twice daily for 7 days; while the control group received a placebo. Clinical data and fresh fecal samples were collected before treatment and on days 5-7 of treatment. Intestinal microbiota diversity and structure were analyzed via 16S rDNA sequencing and bioinformatics [α diversity, β diversity, and linear discriminant analysis effect size (LEfSe)].
RESULTS: Fifty-five patients were included (29 in the control group, 26 in the observation group). There were no significantly differences in gender, age, comorbidities, and baseline sequential organ failure assessment (SOFA), acute physiology and chronic health evaluation II (APACHE II), acute gastrointestinal injury (AGI) classification score, and gastrointestinal failure (GIF) score between the two groups. Compared to the control group, the observation group showed significantly lower serum procalcitonin, APACHE II score, and greater reduction in GIF score by day 7. Thirty fecal samples were collected pre-treatment (baseline group), 29 post-treatment from the control group, and 26 from the observation group. Gut microbiota α diversity analysis revealed that Simpson index in the observation group and control group were significantly decreased compared to the baseline group [0.75 (0.53, 0.91), 0.81 (0.32, 0.91) vs. 0.88 (0.87, 0.89), both P < 0.05], but there was no significantly difference between the observation group and the control group. There were no significantly differences in Chao1, Ace, and Shannon indices among three groups. β diversity analysis indicated that distinct microbiota structures among three groups (R2 = 0.096, P = 0.026). Species difference analysis showed that, at the phylum level, Firmicutes (53.69%), Actinobacteria (16.23%), Proteobacteria (15.39%), and Bacteroidetes (9.57%) dominated, with no significant intergroup differences. At the genus level, 38 taxa showed significant differences. Compared to the control group, the observation group exhibited increased Erysipelatoclostridium (P = 0.014) and Faecalibacterium (P = 0.013), and decreased Bacteroides (P = 0.009), Bilophila (P = 0.005), Eggerthella (P = 0.002), and Collinsella (P = 0.043). LEfSe analysis highlighted Lactobacillus salivarius, Erysipelatoclostridium, Collinsella, Cloacibacillus, and Bacteroides as key discriminators.
CONCLUSION: YHJF combined with conventional therapy alters intestinal microbiota structure in patients with elderly pulmonary-derived sepsis, with Bacteroides, Erysipelatoclostridium, and Collinsella identified as potential microbial targets.
参考来源
- Chen R, Lai J, Zhong M, et al. [Effects of Yiqi Huoxue Jiedu formula on the gut microbiota in elderly patients with pulmonary-derived sepsis based on 16S rDNA sequencing: a multicenter prospective randomized double-blind controlled trial]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40819941. doi:10.3760/cma.j.cn121430-20240820-00709
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。